Norris Perne & French LLP Organon & Co. Transaction History

Norris Perne & French LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 24, 2023	SELL	$23.31 - $28.61 $714,428 - $876,867	-30,649 Reduced 7.52%	377,045 $0
Q3 2022 Oct 13, 2022	SELL	$23.4 - $34.25 $1.88 Million - $2.75 Million	-80,181 Reduced 16.43%	407,694 $9.54 Million
Q2 2022 Aug 11, 2022	BUY	$31.66 - $38.9 $150,733 - $185,202	4,761 Added 0.99%	487,875 $16.5 Million
Q1 2022 Apr 26, 2022	BUY	$30.45 - $39.36 $99,114 - $128,116	3,255 Added 0.68%	483,114 $16.9 Million
Q4 2021 Jan 26, 2022	BUY	$28.67 - $37.13 $349,601 - $452,763	12,194 Added 2.61%	479,859 $14.6 Million
Q3 2021 Oct 26, 2021	BUY	$28.63 - $35.64 $6.47 Million - $8.05 Million	225,925 Added 93.46%	467,665 $15.3 Million
Q2 2021 Jul 20, 2021	BUY	$28.45 - $38.0 $6.88 Million - $9.19 Million	241,740 New	241,740 $7.32 Million

790

201M

1.71M

865K

Ticker OGN
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 254,330,000
Market Cap $4.17B
Description
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...

Get notified when there are updates to the investment portfolio of Norris Perne & French LLP, based on Form 13F filings with the SEC.

Stay updated on Norris Perne & French LLP with notifications on news.